



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

1656  
4/2/03

IN RE APPLICATION OF:

Zalipsky &amp; Gabizon

APPLICATION NO.: 10/057,839

FILED: January 25, 2002

FOR: CONJUGATE HAVING A CLEAVABLE  
LINKAGE FOR USE IN A LIPOSOME

EXAMINER: Unassigned

ART UNIT: 1656

CONF. No: 1653

RECEIVED

FEB 19 2003

TECH CENTER 1600/2900

**Supplemental Information Disclosure Statement Within Three  
Months of Application Filing or Before First Action – 37 CFR 1.97(b)**Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 CFR 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information☒ Copies of the following references are enclosed:☒ References marked by asterisks☒ Copies of the following references can be found in parent U.S. Application No. 09/556,610:☒ References not marked by asterisks☐ The following references are not in English. For each such reference, the undersigned has enclosed (i) a translation of the reference; (ii) a copy of a communication from a foreign patent office or International Searching Authority citing the reference, (iii) a copy of a reference which appears to be an English-language counterpart, or (iv) an English-language abstract

for the reference prepared by a third party. Applicant has not verified that the translation, English-language counterpart or third-party abstract is an accurate representation of the teachings of the non-English reference, though, and reserves the right to demonstrate otherwise.

- ☐ All cited references
- ☐ References marked by ampersands
- ☐ The following:

3. Effect of Information Disclosure Statement (37 CFR 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due. However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 CFR 1.704(d))

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).


Respectfully submitted,

Date: 2-12-03

Judy M. Mohr  
Judy M. Mohr  
Registration No. 38,563

**Correspondence Address:**

Customer No. 22918  
(650) 838-4300

 <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Form PTO-1449 (Modified) Use several sheets if necessary				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/057,839
				Confirmation Number	1653
				Filing Date	January 25, 2002
				First Named Inventor	Zalipsky & Gabizon
				Group Art Unit	1656
				Examiner Name	Unassigned
				Attorney Docket No.	55325.8167.US04
1		of		1	

RECEIVED  
FEB 19 2003  
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
		NUMBER	Kind Code			
		5,891,468		Martin, <i>et al.</i>	04/06/99	

FOREIGN PATENT DOCUMENTS								
Examiner Initial	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
	*	EP	0 317 957	A2	Senter	5/31/89		

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
		Gaber, M., et al., <i>Pharmaceutical Res</i> <u>12</u> (10):1407-1416, (1995).	
		Hirota, S., <i>International J of Pharmaceutics</i> <u>162</u> (1-2):185-194, (1998).	
		Johnsson, M., et al., <i>J of Liposome Res</i> <u>9</u> (1):53-79, (1999).	
		Kirpotin, D., et al., <i>FEBS Letters</i> <u>388</u> :115-118, (1996).	
		Mueller, C.E., et al., <u>322</u> (6):343-350, (1989).	
	*	Senter, P.D., et al., <i>J Org Chem</i> <u>55</u> (9):2975-2978, (1990).	
		Vaage, J., et al., <i>Cancer</i> <u>72</u> (12):3671-3675, (1993).	
		Vaage, J., et al., <i>Cancer</i> <u>73</u> (5):1478-1484, (1994).	
		Vaage, J., et al., <i>International J of Cancer</i> <u>51</u> (6)942-948, (1994).	
		Zalipsky, <i>Bioconj Chem</i> <u>10</u> (5):703-707, (1999).	
		<i>International Journal of Cancer</i> <u>80</u> (1):134-137, (1999).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	